• 1
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 1990; 33: 16072.
  • 2
    Petzke F, Clauw DJ, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: effect of two types of stimuli and ascending versus random modes of presentation [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S173.
  • 3
    Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001; 91: 16575.
  • 4
    Staud R, Carl KE, Vierck CJ, Price DD, Robinson ME, Cannon RL, et al. Repetitive muscle stimuli result in enhanced wind-up of fibromyalgia patients [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S395.
  • 5
    Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science 2000; 288: 176972.
  • 6
    Lorenz J, Grasedyck K, Bromm B. Middle and long latency somatosensory evoked potentials after painful laser stimulation in patients with fibromyalgia syndrome. Electroencephalogr Clin Neurophysiol 1996; 100: 1658.
  • 7
    Mountz JM, Bradley LA, Modell JG, Alexander RW, Triana-Alexander M, Aaron LA, et al. Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995; 38: 9368.
  • 8
    Cianfrini LR, McKendree-Smith NL, Bradley LA, Alarcon GS, Deutsch G, Sotolongo A, et al. Pain sensitivity and bilateral activation of brain structures during pressure stimulation of patients with fibromyalgia (FM) is not mediated by major depression (DEP) [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S395.
  • 9
    Grant MAB, Farrell MJ, Kumar R, Clauw DJ, Cracely RH. FMRI evaluation of pain intensity coding in fibromyalgia patients and controls [abstract]. Arthritis Rheum 2001; 44 Suppl 9 S394.
  • 10
    Vaeroy H, Helle R, Foore O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988; 32: 216.
  • 11
    Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994; 37: 1593601.
  • 12
    Welin M, Bragee B, Nyberg F, Kristiansson M. Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in CSF from fibromyalgia patients [abstract]. J Musculoskeletal Pain 1995; 3: 4.
  • 13
    Bradley LA, Alberts KR, Alarcon GS, Alexander MT, Mountz JM, Wiegent DA, et al. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM) [abstract]. Arthritis Rheum 1996; 39 Suppl 9: S212.
  • 14
    Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994; 37: 158392.
  • 15
    Griep EN, Boersma JW, de Kloet EP. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993; 20: 46974.
  • 16
    Griep EN, Boersma JW, Lentjes EG, Prins AP, ven der Korst JK, de Kloet ER. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol 1998; 25: 137481.
  • 17
    Neeck G, Crofford LJ. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 2000; 26: 9891002.
  • 18
    Martinez-Lavin M, Hermosillo AG, Mendoza C, Ortiz R, Cajigas JC, Pineda C, et al. Orthostatic sympathetic derangement in subjects with fibromyalgia. J Rheumatol 1997; 24: 7148.
  • 19
    Martinez-Lavin M, Hermosillo AG, Rosas M, Soto ME. Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum 1998; 41: 196671.
  • 20
    Kelemen J, Lang E, Balint G, Trocsanyi M, Muller W. Orthostatic sympathetic derangement of baroreflex in patients with fibromyalgia. J Rheumatol 1998; 25: 8235.
  • 21
    Petzke F, Clauw DJ. Sympathetic nervous system function in fibromyalgia. Curr Rheumatol Rep 2000; 2: 11623.
  • 22
    Cohen H, Neumann L, Alhosshle A, Kotler M, Abu-Shakra M, Buskila D. Abnormal sympathovagal balance in men with fibromyalgia. J Rheumatol 2001; 28: 5819.
  • 23
    Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM. Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 1997; 24: 13849.
  • 24
    Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998; 104: 22731.
  • 25
    Hawley DJ, Wolfe F. Pain, disability, and pain/disability relationships in seven rheumatic disorders: a study of 1,522 patients. J Rheumatol 1991; 18: 15527.
  • 26
    Callahan LF, Smith WJ, Pincus T. Self-report questionnaires in five rheumatic diseases: comparisons of health status constructs and associations with formal education level. Arthritis Care Res 1989; 2: 12231.
  • 27
    Wolfe F, Skevington SM. Measuring the epidemiology of distress: the rheumatology distress index. J Rheumatol 2000; 27: 20009.
  • 28
    Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997; 4: 13453.
  • 29
    Clauw DJ, Paul P. The overlap between fibromyalgia and inflammatory rheumatic diseases: when and why does it occur? J Clin Rheumatol 1995; 1: 33541.